1YBottom 25% of the group
Rank 63 of 63 funds
Return −13.51%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 63No. 1 is SCBGENOME(E) +62.13%
United China Healthcare Innovation Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
UCHI is a fund of funds that puts 100.47% into units of other funds, spread across several funds
This fundUCHIThis fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
All funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
WuXi Biologics (Cayman) 2269.HK9.94%
Over the past year it was in the bottom 25% of its group; over 5 years it returned −14.20% per year (Bottom 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| −5.02% | −0.95% | −5.33% | −12.89% | −1.35% | −4.67% | −13.51% | −11.40% | −53.51% | −60.92% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −73.87% Previous peak 28 Jun 2021 (NAV 11.3300) → Trough 13 Jan 2025 (NAV 2.9604) · Not back to the previous peak as of 3 Nov 2026
Currently −65.51% from the peak NAV of 11.3300 (28 Jun 2021)
Over 5 years, UCHI returned -0.45 per unit of volatility, ranking 30 of 33 funds · The highest is FP HCARE-A (0.43)
(1) กองทุนจะลงทุนในหรือมีไว้ซึ่งหน่วยลงทุนของกองทุนรวมตราสารทุนต่างประเทศ และ/หรือกองทุนรวมอีทีเอฟ (ETF) ตราสารทุนต่างประเทศ ที่มีนโยบายการลงทุนในหลักทรัพย์หรือตราสารของบริษัทที่ดำเนินธุรกิจด้านเฮลท์แคร์ (Healthcare) ของประเทศจีน ซึ่งมีความเกี่ยวข้อง หรือได้รับประโยชน์จากการพัฒนานวัตกรรมด้านเฮลท์แคร… Its largest holdings are หน่วยลงทุน : Global X China Biotech 51.95% · หน่วยลงทุน : Kraneshares MSCI All China Health Care Index ETF 48.52% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 23 Feb 2021, its NAV has fallen as much as −73.87% from its peak.
Actual total expense ratio (TER) 1.86% a year, against a ceiling of 5.35%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Innovent Biologics 1801.HK8.62%
Jiangsu Hengrui Pharmaceutic… 600276.SS5.66%WuXi Biologics (Cayman) 2269.HKInnovent Biologics 1801.HKContract research and drug manufacturing for drug companies worldwide
Jiangsu Hengrui Pharmaceutic… 600276.SSHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Based on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 100% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · Global X China Biotech as of 27 Oct 2026 · Kraneshares MSCI All China Health Care Index as of 22 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +3.0 | −1.9 | −3.1 | +1.8 | −8.0 | −2.2 | +8.8 | +6.9 | +4.6 | −11.6 | −1.5 | · | −5.0* |
| 2025 | −3.1 | +10.2 | +4.3 | −2.2 | +6.2 | +4.4 | +17.8 | +3.7 | +2.9 | −7.6 | −2.0 | −6.9 | +28.2 |
| 2024 | −20.5 | +10.9 | −6.9 | +1.2 | −4.8 | −6.3 | +2.4 | −0.4 | +21.2 | −10.6 | +0.9 | −5.0 | −21.6 |
| 2023 | +6.9 | −8.3 | −4.8 | +1.2 | −10.5 | −5.3 | +4.8 | −8.0 | +2.8 | +3.4 | +0.1 | −6.5 | −23.2 |
| 2022 | −13.9 | +1.0 | −5.3 | −13.1 | −3.7 | +15.4 | −4.2 | −8.1 | −15.5 | +0.5 | +13.7 | +1.9 | −31.0 |
Minimum first purchase 0.01 THB, subsequent purchases 0.01 THB. Buy orders accepted until 15:30, sell orders until 14:00, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 89.92% of the value of its foreign investments was hedged